Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
Journal of Cancer Research and Clinical Oncology · 2023-08 · 149 (9) · 5493-5496
DOI: 10.1007/s00432-022-04496-y ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Cancer Research and Clinical Oncology, online erschienen am 05.12.2022. Verfasst von Karin G Schrenk und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Internal Oncology, Clinic of Internal Medicine II, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany. karin.…. Hauptthemen laut MEDLINE: Sarcoma, Soft Tissue Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Jena.
Abstract (Originalsprache)
With the increasing use of next-generation sequencing, highly effective targeted therapies have been emerging as treatment options for several cancer types. Recurrent gene-fusions have been recognized in sarcomas; however, options for targeted therapy remain scarce. Here, we describe a case of a sarcoma, associated with a RET::TRIM33 -fusion gene with an exceptional response to a neoadjuvant therapy with the selective RET inhibitor selpercatinib. Resected tumor revealed subtotal histopathologic response. This is the first report of successful targeted therapy with selpercatinib in RET -fusion-associated sarcomas. As new targeted therapies are under development, similar treatment options may become available for sarcoma patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Internal Oncology, Clinic of Internal Medicine II, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany. karin.schrenk@med.uni-jena.de.
- Clinic of Trauma-, Hand- and Reconstructive Surgery, University Hospital Jena, Jena, Germany.
- Institute of Pathology, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
- Institute of Forensic Medicine, Section of Pathology, University Hospital Jena, Jena, Germany.
- Clinic of Nuclear Medicine, University Hospital Jena, Jena, Germany.
- Institute of Diagnostic and Interventional Radiology, University Hospital Jena, Jena, Germany.
Förderung
- Universitätsklinikum Jena
Zitieren
APA
Schrenk, K. G., Weschenfelder, W., Spiegel, C., Agaimy, A., Stöhr, R., Hartmann, A., Gaßler, N., Drescher, R., Freesmeyer, M., Malouhi, A., Bürckenmeyer, F., Aschenbach, R., Teichgräber, U., Kögler, C., Vogt, M., Hofmann, G. O., & Hochhaus, A. (2023). Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma. Journal of Cancer Research and Clinical Oncology, 149(9), 5493-5496. https://doi.org/10.1007/s00432-022-04496-y
Vancouver
Schrenk KG, Weschenfelder W, Spiegel C, Agaimy A, Stöhr R, Hartmann A, et al. Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma. Journal of Cancer Research and Clinical Oncology. 2023;149(9):5493-5496. doi:10.1007/s00432-022-04496-y
BibTeX
@article{Schrenk2023,
author = {Schrenk, Karin G and Weschenfelder, Wolfram and Spiegel, Christian and Agaimy, Abbas and Stöhr, Robert and Hartmann, Arndt and Gaßler, Nikolaus and Drescher, Robert and Freesmeyer, Martin and Malouhi, Amer and Bürckenmeyer, Florian and Aschenbach, René and Teichgräber, Ulf and Kögler, Christine and Vogt, Matthias and Hofmann, Gunther O and Hochhaus, Andreas},
title = {Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2023},
volume = {149},
number = {9},
pages = {5493--5496},
doi = {10.1007/s00432-022-04496-y}
}
EUVIMED